Liquidia Corp (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of ...

Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarterRecorded second consecutive quarter of profitability MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driv ...